Intact Vascular is advancing clinical science to improve the treatment of peripheral artery disease (PAD) and critical limb ischemia (CLI) following standard and drug-coated balloon angioplasty.

Click on any of the TOBA trials to learn more.

This multi-center, global pivotal study evaluates the Tack Endovascular System® (4F) in patients with critical limb ischemia (CLI) and dissections resulting from percutaneous transluminal angioplasty (PTA) using a standard balloon in the mid/distal popliteal, tibial and/peroneal arteries.

TOBA II is designed to investigate the safety and efficacy of the
Tack Endovascular System® in patients with post-PTA dissection following POBA or Lutonix® DCB angioplasty in the SFA and proximal popliteal arteries.

92.1

%

Dissection Resolution

86.5

%

12m K-M Freedom from CD-TLR

79.3

%

12m K-M Primary Patency

0.5

%

Bail Out Stent Rate

TOBA III is a European multi-center post-CE Mark study that continues the evaluation of dissection repair with the Tack Endovascular System following DCB angioplasty with the IN.PACT™ Admiral™ in the SFA and proximal popliteal arteries.

97.7

%

Dissection Resolution

97.5

%

12m K-M Freedom from CD-TLR

95.1

%

12m K-M Primary Patency

0.6

%

Bail Out Stent Rate

Lutonix® is a registered trademark of BD Interventional.
IN.PACT and Admiral are trademarks of Medtronic, Inc.